Mr. Chien Huang reports

TITAN ANNOUNCES CONAVI MEDICAL TO PRESENT OVERVIEW AT TITAN Q&A SESSION

Conavi Medical Inc. will be joining the previously announced Titan Medical Inc. Q&A (question-and-answer) session to be held on Thursday, Sept. 19, 2024, at 5 p.m. ET, in connection with the proposed business combination between Titan and Conavi to be considered at the annual general meeting of Titan on Sept. 30, 2024. After the Conavi presentation, Titan will provide prepared remarks followed by a Q&A session. Paul Cataford, interim president and chief executive officer, and Chien Huang, chief financial officer, will attend the session on behalf of Titan.

Shareholders are invited to submit questions in advance of the Q&A session to investors@titanmedicalinc.com. Questions will be accepted until Sept. 17, 2024, at 1 p.m. ET. A link to the live audio webcast will be made available on the investors relations section of the company's website.

Tom Looby, CEO of Conavi, will present information on Conavi, including Conavi's patented Novasight Hybrid system for minimally invasive cardiovascular procedures.

About Titan Medical Inc.

Titan, a medical technology company incorporated under the Business Corporations Act (Ontario) and headquartered in Toronto, Ont., has developed an expansive patent portfolio related to the enhancement of robotic assisted surgery (RAS), including through a single access point, and is currently focused on evaluating new opportunities to further develop and license its intellectual property.

About Conavi Medical Inc.

Conavi is a privately owned company focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first system to combine both IVUS (intravascular ultrasound) and OCT (optical coherence tomography) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid system has 510(k) clearance from the U.S. Food and Drug Administration, and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.